[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Multiple Cancer Vaccines to Hit the Shelf in Coming Years, States Kuick Research in Its Report Now Available at MarketPublishers.com

11 May 2016 • by Natalie Aster

LONDON – Cancer vaccines are garnering attention owing to their characteristics such as fewer side effects, high specificity, hypotoxicity and high efficacy levels. Besides, innovations pertaining to new delivery methods have also made them a lucrative choice. Unlike presently available conventional methods, they can be utilised targeting a sub-group of cancers without having an adverse influence on normal cells.

The market size of the cancer vaccine sector is far smaller as against that of other cancer therapeutics market sectors. Owing to nascency of the industry lifecycle and late introduction in the market has resulted in the decrease of their overall share. To tap the marketplace in question, a great many global firms are investing heavily in cancer vaccine R&D. The market penetration is poised to increase on account of the competition amid various pharmacos to grab a larger slice of this market.

All in all, the prospects of cancer vaccines appear to be bright, and a slew of cancer vaccines are set to hit the shelf in the offing.

In-demand report “Global Cancer Vaccine Market & Clinical Trial Insight” drawn up by Kuick Research provides an insightful assessment of the market on a global scale. The study gives an extensive review of the MoA of cancer vaccines, and discusses the adjuvants therapy for them. It further canvasses the worldwide market for cancer vaccines, examines the market dynamics, and provides a future outlook. The study unveils detailed information on the platforms for the delivery of cancer vaccines; includes a discussion on the emergence of personalised cancer vaccines; discusses the public HPV cancer vaccination programme. Furthermore, the study analyses the global cancer vaccines clinical pipeline based on phase, indication, firms and country; covering 298 vaccines in development. The report casts light on the 15 cancer vaccines that are already in the market. An in-depth evaluation of the regulatory landscape is provided, too.

More reports by the publisher are available at Kuick Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest